April 14th, 2022

Shear Insights: HemoShear Therapeutics Presents Pilot Data from MMA and PA Natural History Study

Read More »

The JUMP Study

Read More »
December 14th, 2021

HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

Read More »
November 22nd, 2021

Shear Insights: HemoShear to be Featured at International Metabolic Conference

Read More »
November 16th, 2021

HemoShear Identifies Second Target to Treat Nash for Takeda

Read More »
November 2nd, 2021

Shear Insights: HemoShear Therapeutics Appoints Organizational Development Leader and Recruiter as Company Grows

Read More »
September 29th, 2021

Shear Insights: Susan Klees Appointed by Governor to Virginia’s Newly Established Rare Disease Council

Read More »
September 21st, 2021

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

Read More »
August 4th, 2021

Shear Insights: Brian Wamhoff Recognized as one of the PharmaVOICE 100 Most Inspiring People

Read More »
July 22nd, 2021

HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
May 3rd, 2021

Shear Insights: Peer-Reviewed Journal Publishes the Discovery of HemoShear’s HST5040 Small Molecule in Clinical Development for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
April 21st, 2021

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Read More »
View More +


HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902